Identifying the gaps in human and veterinary chlamydia vaccine development


  • Marga Janse Athena Institute VU Amsterdam, De Boelelaan 1085,1081 HV Amsterdam
  • Marcela Trocha Athena Institute VU Amsterdam, De Boelelaan 1085,1081 HV Amsterdam, The Netherlands
  • Jelle Feddema Athena Institute VU Amsterdam, De Boelelaan 1085,1081 HV Amsterdam, The Netherlands
  • Eric Claassen Athena Institute VU Amsterdam, De Boelelaan 1085,1081 HV Amsterdam, The Netherlands
  • Linda Van de Burgwal Athena Institute VU Amsterdam, De Boelelaan 1085,1081 HV Amsterdam, The Netherlands



Chlamydia infections, Chlamydia vaccine development, Patents, Clinical trials


Background: Chlamydia infections in humans and animals pose a significant burden on health systems worldwide. While widespread screening, adequate treatment, and prevention programs are helpful to increase awareness and improve screening rates, infection rates are rising. A vaccine is necessary to slow increasing rates, manage negative consequences, and prevent possible antibiotic resistance. We present the current landscape regarding the innovations for commercial vaccine development in a “one-health” context.

Methods: We developed a unique dataset containing data of patent documents intended for human and veterinary use, and clinical trials in order to provide a detailed description of the global chlamydia vaccine developments.

Results: Analysis of patents and clinical trials intended for human use presented a vaccine field that is underdeveloped, with no commercial human chlamydia vaccine available, and two potential candidates in a phase 1 clinical trial. Comparing innovations concerning chlamydia vaccine developments for both human and veterinary patents, it was clear that these fields are very different and independent of each other. The field is small, and certain companies and researchers show repeated interest. Partnerships among applicants and those involved in chlamydia vaccine innovation would be an important step to take towards innovating and developing an effective vaccine.

Conclusions: We have shown that North America is considered, by patent application, to hold the most potential for a chlamydia vaccine, specifically against the Chlamydia trachomatis strain. A new vaccine is likely to be a subunit vaccine with components of the major outer membrane protein antigen.


Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N, et al. Global Estimates of the Prevalence and Incidence of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic Review and Global Reporting. PLoS One. 2015;10:e0143304.

Owusu-Edusei Jr K, Chesson HW, Gift TL, Brunham RC, Bolan G. Cost-effectiveness of Chlamydia vaccination programs for young women. Emerging Infect Dis. 2015;21:960.

Redmond SM, Alexander-Kisslig K, Woodhall SC, van den Broek IV, van Bergen J, Ward H, et al. Genital chlamydia prevalence in Europe and non-European high income countries: systematic review and meta-analysis. PLoS One. 2015;10:e0115753.

Unemo M, Bradshaw CS, Hocking JS, de Vries HJC, Francis SC, Mabey D, et al. Sexually transmitted infections: challenges ahead. Lancet Infect Dis. 2017;17:e235-e79.

Sandoz KM, Rockey DD. Antibiotic resistance in Chlamydiae. Future Microbiol. 2010;5:1427-42.

Longbottom D, Livingstone M. Vaccination against chlamydial infections of man and animals. Vet J. 2006;171:263-75.

Hoelzer K, Bielke L, Blake DP, Cox E, Cutting SM, Devriendt B, et al. Vaccines as alternatives to antibiotics for food producing animals. Part 1: challenges and needs. Vet Res. 2018;49:64.

Jansen KU, Anderson AS. The role of vaccines in fighting antimicrobial resistance (AMR). Human Vaccine Immunotherapeut. 2018;14:2142-9.

Sahu R, Verma R, Dixit S, Igietseme JU, Black CM, Duncan S, et al. Future of human Chlamydia vaccine: potential of self-adjuvanting biodegradable nanoparticles as safe vaccine delivery vehicles. Expert Rev Vaccines. 2018;17:217-27.

Gottlieb SL, Johnston C. Future prospects for new vaccines against sexually transmitted infections. Current Opinion Infect Dis. 2017;30:77.

Stevens H, Debackere K, Goldman M, Mahoney RT, Stevens P, Huys I. Vaccines: Accelerating Innovation and Access. Glob Challenges Report Geneva: WIPO, 2017.

Maslow JN. Challenges and solutions in the development of vaccines against emerging and neglected infectious diseases. Human Vaccines Immunotherapeut. 2019;15:2230-4.

Van de Burgwal LHM, Van der Waal MB, Claassen E. Accelerating microbiota product development: The Societal Impact Value Cycle as a conceptual model to shape and improve public-private valorization processes. Pharma Nutr. 2018;6:157-68.

Van de Burgwal L, Ribeiro CDS, Van der Waal M, Claassen E. Towards improved process efficiency in vaccine innovation: The Vaccine Innovation Cycle as a validated, conceptual stage-gate model. Vaccine. 2018;36:7496-508.

Neevel AM, Urias E, Claassen E, van de Burgwal LH. Quantity versus quality: an assessment of the current pipeline for rabies. Trop Med Int Health. 2019.

Arundel A, Patel P, editors. Strategic patenting. Background report for the Trend Chart Policy Benchmarking Workshop" New Trends in IPR Policy; 2003.

Jürgens B, Herrero-Solana V. Espacenet, Patentscope and Depatisnet: A comparison approach. World Patent Info. 2015;42:4-12.

Abraham S, Juel HB, Bang P, Cheeseman HM, Dohn RB, Cole T, et al. Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial. The Lancet Infect Dis. 2019;19:1091-100.

Russell AN, Zheng X, O'Connell CM, Taylor BD, Wiesenfeld HC, Hillier SL, et al. Analysis of factors driving incident and ascending infection and the role of serum antibody in Chlamydia trachomatis genital tract infection. J Infect Dis. 2016;213:523-31.

Holmes KK. The Chlamydia epidemic. JAMA. 1981;245:1718-23.

Cha S, Newman DR, Rahman M, Peterman TA. High Rates of Repeat Chlamydial Infections Among Young Women—Louisiana, 2000–2015. Sexually Transmitted Dis. 2019;46:52-7.

Phillips S, Quigley BL, Timms P. Seventy Years of Chlamydia Vaccine Research - Limitations of the Past and Directions for the Future. Front Microbiol. 2019;10:70.

Wyrick PB. Chlamydia trachomatis persistence in vitro: an overview. J Infect Dis. 2010;201:S88-S95.

Poston TB, Gottlieb SL, Darville T. Status of vaccine research and development of vaccines for Chlamydia trachomatis infection. Vaccine. 2019;37:7289-94.

Cheong HC, Lee CYQ, Cheok YY, Tan GMY, Looi CY, Wong WF. Chlamydiaceae: diseases in primary hosts and zoonosis. Microorganisms. 2019;7:146.

Yin L, Kalmar I, Boden J, Vanrompay D. Chlamydial infections in Chinese livestock. Rev Sci Tech. 2013;32:817-31.

Yin L, Kalmar I, Boden J, Vanrompay D. Chlamydia psittaci infections in Chinese poultry: a literature review. World's Poultry Sci J. 2015;71:473-82.

Van den Nieuwboer M, Van De Burgwal L, Claassen E. A quantitative key-opinion-leader analysis of innovation barriers in probiotic research and development: valorisation and improving the tech transfer cycle. Pharma Nutr. 2016;4:9-18.

Kumar A, Sharma D, Kumar R. Zoonoses at the Human-Avian Interface: A Review. BAOJ Vet Sci. 2018;2.

Ernst H. The use of patent data for technological forecasting: The diffusion of CNC-technology in the machine tool industry. Small Business Economics. 1997;9:361-81.

Fernald KDS, Weenen TC, Sibley KJ, Claassen E. Limits of Biotechnol Innov. 2013.

Weenen TC, Fernald K, Pronker ES, Commandeur H, Claassen E. Bridging a pharma-like innovation gap in medical nutrition. Pharma-Nutrition: Springer; 2014: 29-52.

Stary G, Olive A, Radovic-Moreno AF, Gondek D, Alvarez D, Basto PA, et al. VACCINES. A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells. Science. 2015;348:8205.

Follmann F, Kosenkrands I, Olsen A, Andersen P. Vaccines against Chlamydia sp. Google Patents; 2019.

Caldwell HD, Kromhout J, Schachter J. Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis. Infection Immunity. 1981;31:1161-76.

Farris CM, Morrison RP. Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model. Infection Immunity. 2011;79:986-96.

Mabey DC, Hu V, Bailey RL, Burton MJ, Holland MJ. Towards a safe and effective chlamydial vaccine: lessons from the eye. Vaccine. 2014;32:1572-8.

Luan X, Peng B, Li Z, Tang L, Chen C, Chen L, et al. Vaccination with MIP or Pgp3 induces cross-serovar protection against chlamydial genital tract infection in mice. Immunobiology. 2019;224:223-30.

Yu H, Karunakaran KP, Jiang X, Chan Q, Rose C, Foster LJ, et al. Comparison of Chlamydia outer membrane complex to recombinant outer membrane proteins as vaccine. Vaccine. 2020.

Pronker E. Innovation Paradox in Vaccine Target Selection (No. EPS-2013-282-S&E). ERIM Ph.D. Series Research in Management. Erasmus Research Institute of Management. Available at: Accessed on 11 April 2013.






Original Research Articles